Skip to main content
Besponsa .25 mg/mL injection, powder, lyophilized, for solution by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Besponsa, .25 mg/mL, injection, powder, lyophilized, for solution Drug class: CD22-directed Immunoconjugate. Available on prescription only. Listed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc..
Prescription only

Besponsa

inotuzumab ozogamicin

Listed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

Strength
.25 mg/mL
Form
Injection, Powder, Lyophilized, For Solution
Route
Intravenous
Class
CD22-directed Immunoconjugate

What it contains

  • Inotuzumab Ozogamicin .25 mg/mL

FDA record

Dosage form Injection, Powder, Lyophilized, For Solution
Route Intravenous
Drug class CD22-directed Immunoconjugate
Approval route BLA — biologic licence
NDC code 0008-0100
FDA application BLA761040
RxNorm concept 1942954
Package sizes listed 1
Marketed since August 2017

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.